WO2004019912A3 - Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer - Google Patents

Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer Download PDF

Info

Publication number
WO2004019912A3
WO2004019912A3 PCT/US2003/026860 US0326860W WO2004019912A3 WO 2004019912 A3 WO2004019912 A3 WO 2004019912A3 US 0326860 W US0326860 W US 0326860W WO 2004019912 A3 WO2004019912 A3 WO 2004019912A3
Authority
WO
WIPO (PCT)
Prior art keywords
polar
buccal
polar solvent
active compound
flavoring agent
Prior art date
Application number
PCT/US2003/026860
Other languages
French (fr)
Other versions
WO2004019912A2 (en
Inventor
Harry A Dugger Iii
Original Assignee
Novadel Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novadel Pharma Inc filed Critical Novadel Pharma Inc
Priority to CA002497136A priority Critical patent/CA2497136A1/en
Priority to EP03791859A priority patent/EP1545458A2/en
Priority to AU2003262917A priority patent/AU2003262917A1/en
Priority to JP2004531575A priority patent/JP2006502150A/en
Publication of WO2004019912A2 publication Critical patent/WO2004019912A2/en
Publication of WO2004019912A3 publication Critical patent/WO2004019912A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.
PCT/US2003/026860 2002-08-29 2003-08-27 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer WO2004019912A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002497136A CA2497136A1 (en) 2002-08-29 2003-08-27 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer
EP03791859A EP1545458A2 (en) 2002-08-29 2003-08-27 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer
AU2003262917A AU2003262917A1 (en) 2002-08-29 2003-08-27 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer
JP2004531575A JP2006502150A (en) 2002-08-29 2003-08-27 Oral polar and nonpolar sprays or capsules containing drugs for the treatment of infectious diseases or cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/230,080 US20030082107A1 (en) 1997-10-01 2002-08-29 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US10/230,080 2002-08-29

Publications (2)

Publication Number Publication Date
WO2004019912A2 WO2004019912A2 (en) 2004-03-11
WO2004019912A3 true WO2004019912A3 (en) 2004-08-19

Family

ID=31976400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026860 WO2004019912A2 (en) 2002-08-29 2003-08-27 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer

Country Status (6)

Country Link
US (3) US20030082107A1 (en)
EP (1) EP1545458A2 (en)
JP (1) JP2006502150A (en)
AU (1) AU2003262917A1 (en)
CA (1) CA2497136A1 (en)
WO (1) WO2004019912A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
EP1036561A1 (en) * 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Buccal, non-polar spray
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
DE10035156A1 (en) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh New protein complex containing complex protein from botulinum toxin, useful for oral delivery of therapeutic polypeptide or low molecular weight pharmaceutical
KR20050018250A (en) * 2003-08-14 2005-02-23 한영주 Composition having anti-cancer activity comprising crude drug complex
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
CN101076317A (en) * 2004-11-01 2007-11-21 瑞拉医药公司 Method of reducing nosocomial infections
ES2490595T3 (en) * 2005-02-17 2014-09-04 Abbott Laboratories Transmucosal administration of drug compositions to treat and prevent disorders in animals
WO2006093786A2 (en) * 2005-02-25 2006-09-08 University Of Kentucky Research Foundation Scopolamine sublingual spray
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
GB0509719D0 (en) * 2005-05-12 2005-06-22 Arakis Ltd Sublingual composition
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
AU2006249761A1 (en) * 2005-05-25 2006-11-30 Transcept Pharmaceuticals, Inc. Solid compositions and methods for treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
ES2535233T3 (en) 2006-01-25 2015-05-06 Insys Therapeutics, Inc. Spraying sublingual fentanyl
US20070248548A1 (en) * 2006-04-19 2007-10-25 Blondino Frank E Stable hydroalcoholic oral spray formulations and methods
JP2010513525A (en) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド Stable anti-emetic oral spray formulations and methods
BRPI0811430A2 (en) * 2007-05-10 2015-06-23 Novadel Pharma Inc Anti-Insomnia Compositions and Processes
US8486973B2 (en) 2007-08-02 2013-07-16 Insys Therapeutics, Inc. Sublingual fentanyl spray
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
KR20110091510A (en) 2008-10-07 2011-08-11 엠펙스 파마슈티컬즈, 인코포레이티드 Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
SI2424523T1 (en) * 2009-04-23 2012-11-30 Londonpharma Ltd Sublingual spray formulation comprising dihydroartemesinin
PL2473170T3 (en) 2009-09-04 2020-03-31 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
BR112012023877A2 (en) * 2010-03-15 2016-08-02 Univ Virginia Commonwealth aerosolized dapsone as a therapy for airway inflammation and abnormal mucociliary transport
RU2013139247A (en) 2011-02-23 2015-03-27 Церулеус Лтд. FLUMAZENIL COMPLEXES CONTAINING THEIR COMPOSITIONS AND THEIR APPLICATIONS
RU2611403C1 (en) 2011-12-05 2017-02-21 Суда Лимитед Compositions in the form of a spray for oral administration and methods of the sildenafil administration
ITMI20131147A1 (en) 2013-07-09 2015-01-10 Biofer Spa NEW WAY OF ADMINISTRATION OF THE IRON, AND NEW FORMULATIONS SUITABLE FOR THIS PURPOSE.
US20230405034A1 (en) * 2020-09-30 2023-12-21 Procaps S.A. Formulation of ivermectin in soft gelatin capsules

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290540A (en) * 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
US20020102218A1 (en) * 2000-12-01 2002-08-01 Cowan Siu Man L. Stable, aerosolizable suspensions of proteins in ethanol
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632504A (en) * 1962-05-24
US3304230A (en) * 1963-02-18 1967-02-14 Revlon Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines
SU432703A3 (en) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
IL52045A (en) * 1976-08-25 1979-12-30 Mundipharma Ag Sprayable germicidal foam compositions
SE7812207L (en) * 1977-12-01 1979-06-02 Welsh Nat School Med APPARATUS, PROCEDURE AND MANUFACTURED PRODUCTS FOR USE IN THE ADMINISTRATION OF ANTIHISTAMINES
US4495168A (en) * 1983-08-22 1985-01-22 Basf Wyandotte Corporation Aerosol gel
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
DE3522550A1 (en) * 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab SPRAYABLE PHARMACEUTICAL PREPARATION FOR TOPICAL APPLICATION
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
DE3544692A1 (en) * 1985-12-18 1987-06-19 Bayer Ag DIHYDROPYRIDINE SPRAY, METHOD FOR THE PRODUCTION THEREOF AND ITS PHARMACEUTICAL USE
US4689233A (en) * 1986-01-06 1987-08-25 Siegfried Aktiengesellschaft Coronary therapeutic agent in the form of soft gelatin capsules
EP0259383B1 (en) * 1986-03-10 1991-01-23 Kurt Dr. Burghart Pharmaceutical preparation and process for preparing the same
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
JPH0645538B2 (en) * 1987-09-30 1994-06-15 日本化薬株式会社 Nitroglycerin spray
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
HU199678B (en) * 1988-07-08 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing aerosols containing nitroglicerol
US5128132A (en) * 1988-11-22 1992-07-07 Parnell Pharmaceuticals, Inc. Eriodictyon compositions and methods for treating internal mucous membranes
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5428066A (en) * 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
DE4007705C1 (en) * 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
AU7547891A (en) * 1990-03-30 1991-10-30 Yasunori Morimoto Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
JP3219096B2 (en) * 1990-05-10 2001-10-15 ニコメド ファーマ エイエス Pharmaceutical preparations containing n-glycolfurols and n-ethylene glycols
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5135753A (en) * 1991-03-12 1992-08-04 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5457100A (en) * 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
CA2145418A1 (en) * 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
US5981591A (en) * 1992-12-04 1999-11-09 Mayor Pharmaceutical Laboratories, Inc. Sprayable analgesic composition and method of use
DE69413955T2 (en) * 1993-03-17 1999-04-01 Minnesota Mining & Mfg AEROSOL COMPOSITION CONTAINING A DERIVATIVE DERIVATIVE FROM ESTER, AMID OR MERCAPTOESTER
JP3399578B2 (en) * 1993-03-22 2003-04-21 株式会社資生堂 Aerosol composition
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5502076A (en) * 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
WO1995031182A1 (en) * 1994-05-13 1995-11-23 Aradigm Corporation Narcotic containing aerosol formulation
US5519059A (en) * 1994-08-17 1996-05-21 Sawaya; Assad S. Antifungal formulation
US5456677A (en) * 1994-08-22 1995-10-10 Spector; John E. Method for oral spray administration of caffeine
IT1268685B1 (en) * 1994-12-27 1997-03-06 Silca Spa KEY UNIT AND CYLINDER LOCK
US5563177A (en) * 1995-01-30 1996-10-08 American Home Products Corporation Taste masking guaifenesin containing liquids
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US6258032B1 (en) * 1997-01-29 2001-07-10 William M. Hammesfahr Method of diagnosis and treatment and related compositions and apparatus
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
ES2234010T3 (en) * 1996-04-12 2005-06-16 Novadel Pharma Inc. POLAR ORAL SPRAY.
US5869082A (en) * 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US6271240B1 (en) * 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6212227B1 (en) * 1997-12-02 2001-04-03 Conexant Systems, Inc. Constant envelope modulation for splitterless DSL transmission
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
JP3127918B1 (en) * 1999-07-14 2001-01-29 住友電気工業株式会社 Road-to-vehicle communication system, roadside communication station and on-vehicle mobile station
CO5271697A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
DE60126599T2 (en) * 2000-03-09 2007-11-22 G W Pharma Ltd., Salisbury CANNABIS CONTAINING PHARMACEUTICAL COMPOSITIONS
WO2001072338A1 (en) * 2000-03-28 2001-10-04 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
US20030096281A1 (en) * 2001-09-14 2003-05-22 Ganesh Venkataraman Methods of making glycomolecules with enhanced activities and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290540A (en) * 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
EP1029536A1 (en) * 1997-10-01 2000-08-23 Flemington Pharmaceutical Corporation Buccal non-polar spray
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
US20020102218A1 (en) * 2000-12-01 2002-08-01 Cowan Siu Man L. Stable, aerosolizable suspensions of proteins in ethanol
US20020110524A1 (en) * 2000-12-01 2002-08-15 Cowan Siu Man L. Method for stabilizing biomolecules in liquid formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE FILE REGISTRY [online] XP002266750, Database accession no. RN-188039-54-5 *

Also Published As

Publication number Publication date
US20050142069A1 (en) 2005-06-30
WO2004019912A2 (en) 2004-03-11
AU2003262917A1 (en) 2004-03-19
CA2497136A1 (en) 2004-03-11
JP2006502150A (en) 2006-01-19
US20030082107A1 (en) 2003-05-01
EP1545458A2 (en) 2005-06-29
US20090186035A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
WO2004019912A3 (en) Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer
WO2004043428A3 (en) Buccal, polar and non-polar spray or capsule containing drugs for treating pain
WO2004019910A3 (en) Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
WO2004035021A3 (en) Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO2004019909A3 (en) Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
WO2004019911A3 (en) Buccal, polar or non-polar spray or capsule containing drugs for treating endocrine disorders
WO2005030167A3 (en) Buccal, polar and non-polar spray containing alprazolam
ATE237322T1 (en) NON-POLAR NITROGLYCERIN SPRAY FOR BUCCAL ADMINISTRATION
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
WO2004026231A3 (en) Formulation for lipophilic agents
WO2003053350A3 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
WO2003045331A3 (en) Formulations for oral administration of cromolyn sodium
ATE288255T1 (en) POLAR BUCCAL SPRAY
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
WO2004016277A3 (en) Extraction of pharmaceutically active cannabinoids from plant materials
WO2005065318A3 (en) Effervescent oral opiate dosage form
WO2007123955A3 (en) Stable hydroalcoholic oral spray formulations and methods
BE2011C013I2 (en)
WO2004073632A3 (en) Rapid absorption selective 5-ht agonist formulations
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
AU6633801A (en) Medicinal compositions for angiogenic therapy
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2497136

Country of ref document: CA

Ref document number: 2004531575

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003791859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003262917

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 539278

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2003791859

Country of ref document: EP